By Ben Glickman

HilleVax on Thursday named Sean McLoughlin as the vaccine developer's next operating chief.

The Boston-based biopharmaceutical company said that co-founder and current COO Aditya Kohli will become chief business officer as part of a planned transition.

McLoughlin, 52, recently served as global vaccine commercialization lead, RSV at GSK. He has held various roles at GSK over 25 years with the company.

McLoughlin will receive an annual base salary of $450,000, with an annual target bonus of 45% of his salary and a sign-on bonus of $200,000.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

January 18, 2024 07:34 ET (12:34 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more GSK Charts.